DiaMedica Therapeutics (NASDAQ:DMAC) Upgraded at Wall Street Zen

Key Points

• Wall Street Zen upgraded DiaMedica Therapeutics from “sell” to “hold,” while the broader analyst consensus remains “Moderate Buy,” with four Buy ratings and one Sell rating.
• DMAC opened at $8.72, compared with a 12-month range of $5.24 to $10.42. Analysts cited in the report maintain an average price target of $12.00.
• DiaMedica reported quarterly adjusted losses of $0.19 per share, narrowly beating estimates of $0.20, and institutional investors currently own 10.12% of the company.

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued on Saturday, Wall Street Zen reports.

DMAC has been the topic of a number of other reports. HC Wainwright reissued a "buy" rating and set a $12.00 price target on shares of DiaMedica Therapeutics in a report on Tuesday, August 11th. Weiss Ratings reiterated a "sell (d-)" rating on shares of DiaMedica Therapeutics in a research report on Thursday, October 15th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, DiaMedica Therapeutics has an average rating of "Moderate Buy" and an average target price of $12.00.

DiaMedica Therapeutics Trading Up 1.0%

NASDAQ DMAC opened at $8.72 on Friday. DiaMedica Therapeutics has a 12 month low of $5.24 and a 12 month high of $10.42. The stock has a market cap of $470.27 million, a price-to-earnings ratio of -12.11 and a beta of 0.92. The company's 50 day moving average is $7.35 and its two-hundred day moving average is $6.77.

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.19) earnings per share for the quarter, topping analysts' consensus estimates of ($0.20) by $0.01. Sell-side analysts forecast that DiaMedica Therapeutics will post -0.84 EPS for the current year.

Institutional Trading of DiaMedica Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. AWM Investment Company Inc. bought a new position in shares of DiaMedica Therapeutics during the 2nd quarter valued at about $253,000. Bank of America Corp DE increased its stake in DiaMedica Therapeutics by 62.5% in the 1st quarter. Bank of America Corp DE now owns 42,768 shares of the company's stock worth $290,000 after acquiring an additional 16,446 shares during the last quarter. World Investment Advisors increased its stake in DiaMedica Therapeutics by 7.7% in the 4th quarter. World Investment Advisors now owns 36,975 shares of the company's stock worth $294,000 after acquiring an additional 2,650 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in shares of DiaMedica Therapeutics during the 1st quarter worth approximately $356,000. Finally, Sei Investments Co. raised its holdings in shares of DiaMedica Therapeutics by 100.0% during the 1st quarter. Sei Investments Co. now owns 111,320 shares of the company's stock worth $754,000 after acquiring an additional 55,660 shares in the last quarter. 10.12% of the stock is currently owned by institutional investors.

About DiaMedica Therapeutics

DiaMedica Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for serious diseases affecting the kidneys and nervous system. The company's research is centered on therapies intended to address conditions with limited treatment options.

DiaMedica's lead investigational product is DM199, a recombinant form of human tissue kallikrein-1, an enzyme involved in blood flow regulation and vascular function. The company has evaluated DM199 in clinical development programs targeting acute ischemic stroke and kidney-related diseases, including chronic kidney disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.